April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i
Nov 19, 2023, 17:20

Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i

Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:

Capivasertib is now approved in combo with fulvestrant for pts with pretreated ER+/HER2- MBC whose tumor has an alteration in PIK3CA, AKT1 or PTEN (approx 40%).

More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i.”

For more information click here.
Source: Paolo Tarantino/Twitter